Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . . especially in those taking prolactin-raising antipsychotics who are at high risk of fracture.”
In the November issue of Medicine, Dr. Tseng of Tsyr-Huey Mental Hospital in Kaohsiung City and colleagues note that it has not been possible to separate the effects of medication and of schizophrenia itself. Studies in drug-free patients or those receiving a short course of antipsychotics have had conflicting results.
To gain further information, the team did a meta-analysis of 13 studies comparing BMD of patients with schizophrenia and healthy controls. The eight studies that gave numbers of enrollees involved a total of 2,214 patients and 1,840 controls.